drugset / Trial / NCT03016598

Stimulant Oxytocin Study

NCT03016598 ↗

Phase 2 Completed 42 enrolled VA Office of Research and Development
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with stimulant use disorders and enrolled in opioid replacement therapy (ORT) program for co-occurring opioid use disorder (OUD).

Timeline

Start
2018-01-26
Primary completion
2020-02-14
Completion
2020-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 40 iu Intranasal

Indications